The aim of the study was to analyze the SF3B1 mutation and the proposed SF3B1 entity in a large cohort of 734 MDS patients with respect to the incidence, genomic landscape, AML transformation rate and clinical outcome. Here, SF3B1 is linked to acute myeloid leukemia.